Genfit S.A. (OTCMKTS:GNFTF) Sees Large Drop in Short Interest

Genfit S.A. (OTCMKTS:GNFTF) was the recipient of a significant decrease in short interest in August. As of August 14th, there was short interest totaling 763 shares, a decrease of 72.8% from the July 30th total of 2,805 shares. Based on an average daily trading volume, of 8 shares, the short-interest ratio is presently 95.4 days.

Genfit Price Performance

GNFTF remained flat at $15.75 during trading on Friday. Genfit has a 12 month low of $4.14 and a 12 month high of $16.50. The business has a fifty day simple moving average of $13.65 and a two-hundred day simple moving average of $11.26.

Genfit Company Profile

Genfit is a clinical‐stage biopharmaceutical company headquartered in Lille, France, specializing in the development of innovative therapies and diagnostics for liver and metabolic diseases. The company’s research and development efforts are primarily focused on non‐alcoholic steatohepatitis (NASH), a progressive liver disorder with significant unmet medical needs. Genfit’s lead therapeutic candidate, elafibranor, is designed to target key pathways involved in inflammation, fibrosis and lipid metabolism, positioning it as a potential treatment for patients with NASH and associated metabolic complications.

In addition to its therapeutic pipeline, Genfit has established a diagnostic arm centered on NIS4®, a proprietary blood‐based test that leverages transcriptomic biomarkers to enable earlier and more accurate detection of liver fibrosis in patients at risk for NASH.